An interventional study of Cardiac MRI in Breast Cancer, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 66 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Breast Neoplasms by Wake Forest University Health Sciences — 5 open to participants now, 12 under way, none of them phase 3. Breast Neoplasms · Wake Forest University Health Sciences.
Among the 67 studies in Breast Neoplasms by Wake Forest University Health Sciences, this one is the 2nd largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2017, is one of 30 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 38th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 67 studies in Breast Neoplasms by Wake Forest University Health Sciences are open now, in 2 countries. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18–45 · Women only
Wake Forest University Health Sciences · Sites in United States
Ages 18–85
Wake Forest University Health Sciences · Sites in United States, Puerto Rico
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 3
First in 1996; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 403 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 30 across the 49 interventional studies, 44 across the 18 observational. Of the 49 that completed or were terminated, 19 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
3 of the studies in Breast Neoplasms by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02422641Wake Forest University Health SciencesProspective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis | 2026-12 |
| NCT07009093Wake Forest University Health SciencesUtility of a Mobile Application for Young Women With Breast Cancer | 2027-07 |
| NCT06216574Wake Forest University Health SciencesDeveloping an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial | 2027-08-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 67 studies in Breast Neoplasms by Wake Forest University Health Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to see if patients receiving chemotherapy for breast cancer affects the heart, the ability to exercise and fatigue when compared to patients who do not have cancer.
840 women aged ≥18 years old scheduled to receive chemotherapy for Stage I-III breast cancer and a comparison population of 160 women without cancer (1,000 total). Equal numbers of women will be recruited aged \< 52 vs. > 52. At baseline, innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers will be collected.
Measurements will be repeated at 3±1, 12±2 and 24±2 months. This study will assess the relevance of pre-existing factors such as age, black/white race, hypertension, smoking (yes/no), diabetes, coronary artery disease, menopause status, CV medications, and physical activity on the study outcomes. Also, this study will assess dynamic change in modifiable CV risk factors (including BMI, blood pressure, serum lipids, serum glucose, physical activity, psychosocial factors, lifestyle behaviors), and the cancer treatment including chemotherapy, radiation therapy, immunotherapy, and surgery.
Inclusion Criteria for Women with Stage I - III Breast Cancer:
Exclusion Criteria for Women with Stage I-III Breast Cancer:
Within the past 6 months:
Within the past month:
Inclusion Criteria for Women Free of Cancer for Comparison:
Exclusion Criteria for Women Free of Cancer for Comparison:
Within the past 6 months:
Within the past month:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Breast cancer patients receiving non-anthracycline or anthracycline chemotherapy Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers. Measurements will be repeated at 3±1, 12±2 and 24±2 months after initiation of chemotherapy treatment.
Diagnostic Test: Cardiac MRI
Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers. Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of baseline activities.
Diagnostic Test: Cardiac MRI
Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months. Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months.
FACT-Fatigue
Participants rate the degree to which each item applies in the past 7 days prior to Baseline using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.
Time frame: Baseline
Change in FACT-Fatigue Results
Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.
Time frame: Baseline and 3 months
Change in FACT-Fatigue Results
Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.
Time frame: Baseline, 3 months and 12 months
Change in FACT-Fatigue Results
Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.
Time frame: Baseline, 3 months, 12 months and 24 months
Change in MRI Exam Results
The exam will measure left ventricular volumes, ejection fraction, myocardial strain/strain rate, mass, mapping, aortic pulse wave velocity and aortic wall thickness. The exam will take 10 - 15 minutes to complete.
Time frame: Baseline, 3 months and 24 months
Change in 6 Minute Walk Results
The purpose of this test is to find out how far the participant can walk in 6 minutes.
Time frame: Baseline, 3 months, 12 months and 24 months
Cohen's 4-item Perceived Stress Scale (PSS)
A summed scale asking how often over the prior two weeks four aspects of stress were experienced (1=never to 5=very often) o weeks four aspects of stress were experienced (1=never to 5=very often)
Time frame: Baseline, 3 months, 12 months, and 24 months
Cook-Medley Hostility Scale
A 14-item scale used to assess the effect of hostility associated with cardiovascular risk factors. Minimum Score: 0 Maximum Score: 13 Higher values indicate greater hostility.
Time frame: Baseline
Changes in FACT-Fatigue Results
Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.
Time frame: Baseline, 3 months, 12 months, and 24 months
6 Minute Walk Results
The purpose of this test is to find out how far the participant can walk in 6 minutes.
Time frame: Baseline, 3 months, 12 months and 24 months
RAND MOS 36-item Short Form Health Survey (SF-36)
SF-36 consists of 36 items measuring the following 8 domains: physical function, role limitations due to physical health problems, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional health problems, and mental health. These 8 domains also provide two summary scores.
Time frame: Baseline, 3 months, 12 months and 24 months
Center for Epidemiological Studies Depression Scale (CESD-10)
Screening questionnaire assessing depressive symptoms during the last week
Time frame: Baseline, 3 months, 12 months and 24 months
Godin Leisure-Time Exercise Questionnaire (LTEQ)
Main process measure of physical activity participation
Time frame: Baseline, 3 months, 12 months and 24 months
PACE Adult Sedentary Behaviors Survey
Assess sedentary lifestyle behaviors
Time frame: Baseline, 3 months, 12 months and 24 months
PROMIS Short Form 8A Measure of Sleep Disturbance
Assess time course and risk factors associated with sleep disturbance and fatigue Minimum Score: Raw: 8, T-score: 28.9 Maximum Score: Raw: 40, T-score: 76.5 Higher values represent greater sleep disturbance.
Time frame: Baseline, 3 months, 12 months and 24 months
PROMIS Applied Cognitive Abilities Short Form 8A and Applied Cognition General Concerns Short Form 8A
Measurement of different aspects of cognitive functioning. PROMIS Applied Cognitive Abilities Short Form 8A \- Minimum Score: Raw: 8, T-score: 27.0 Maximum Score: Raw: 40, T-score: 64.8 Higher values represent better cognition. Applied Cognition General Concerns Short Form 8A \- Minimum Score: Raw: 8, T-score: 23.3 Maximum Score: Raw: 40, T-score: 62.7 Higher values represent better cognition.
Time frame: Baseline, 3 months, 12 months and 24 months
Walking Efficacy for Duration Scale
Comprised of six items and will be included as a measure of exercise capacity
Time frame: Baseline, 3 months, 12 months and 24 months
Chair Stands - Measures Leg Strength
Participants will be first asked to stand from a sitting position without using their arms. If they can perform the task, they will then be asked to stand up and sit down five times as quickly as possible. The time to complete the task will be recorded.
Time frame: Baseline, 3 months, 12 months and 24 months
Standing Balance Test
Participants will be asked to maintain balance for up to 30 seconds in three positions characterized by a progressive narrowing of the base support.
Time frame: Baseline, 3 months, 12 months and 24 months
Gait Speed Test
Participants will be instructed to start at a marked walking course with toes touching the start line and when cued to start, will begin walking at their ususal speed. The time to walk from the starting line to the end of the 4-meter walk will be recorded.
Time frame: Baseline, 3 months, 12 months and 24 months
Grip Strength
Grip strength is assessed with an isometric handgrip dynamometer while the participant is sitting with the head facing straight ahead. The elbow should be bent at a 90 degree angle and the wrist should be at the mid-prone position.
Time frame: Baseline, 3 months, 12 months and 24 months
Range of Motion
Range of motion at the shoulder joint will be assessed with shoulder flexion and shoulder abduction with a goniometer.
Time frame: Baseline, 3 months, 12 months and 24 months
KCCQ-12 Questionnaire
Independently measures the patient's perception of their health status which includes heart failure symptoms (frequency and burden), physical and social limitations, and how their heart failure impacts their QOL within a 2-week recall period.
Time frame: Baseline, 24 months
B-type natriuretic peptide (BNP)
Serum BNP as a predictor of exercise intolerance
Time frame: Baseline and 24 months
Troponin - 1
Acquired to determine associations between troponin levels during therapy and the onset of cardiac and vascular dysfunction, exercise capacity, and fatigue.
Time frame: Baseline and 3 months
Plan to share: Yes — Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.
Time frame: 6 months after publication for a 2 year duration
Access criteria: upon request to NCORP@wakehealth.edu
Started Jul 2017 (actual). Primary completion is estimated for Jul 2032, 180 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 180 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jul 2034 → Jul 2032 and completion Jul 2034 → Jul 2032.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →